Clinical trial
Study of Picoplatin Efficacy After Relapse
NCT00465491 · Poniard Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00465491 |
|---|---|
| Title | Study of Picoplatin Efficacy After Relapse |
| Official title | A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy. |
| Acronym | SPEAR |
| Lead sponsor | Poniard Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | picoplatin, best supportive care |
| Enrollment | 399 |
| Start date | Apr 1, 2007 |
| Primary completion | May 1, 2009 |
| First posted | Apr 25, 2007 |
| Last update posted | Apr 14, 2009 |
| Countries | Argentina, Belarus, Bosnia and Herzegovina, Bulgaria, Chile, Croatia, Hungary, India, Latvia, Montenegro, Poland, Romania and 3 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: